论文部分内容阅读
目的观察普罗布考治疗对早期糖尿病肾病的尿微量白蛋白的影响。方法将53例2型糖尿病患者随即分为两组:对照组27例,常规药物治疗(包括降糖、降压、调脂、抗血小板聚集等);普罗布考组26例,在常规药物治疗的基础上口服普罗布考片0.5g、每日2次口服,两组治疗3个月。比较两组治疗前后尿中微量白蛋白、血糖、血脂、高敏C-反应蛋白、纤维蛋白原水平。结果与治疗前比较,两组治疗后血糖、血脂、血压、尿微量白蛋白均明显下降(P<0.05);治疗后两组患者的血糖、血脂、血压水平组间差别无统计学意义(P>0.05)。而普罗布考组的hs-CRP、纤维蛋白原水平、尿微量白蛋白较常规药物组有明显下降,组间差别有统计学意义(P<0.05)。结论在常规药物治疗的基础上,联合普罗布考,能有效降低尿微量白蛋白,对早期糖尿病肾病有治疗作用。
Objective To observe the effect of probucol treatment on urinary albumin in patients with early diabetic nephropathy. Methods Fifty-three patients with type 2 diabetes were randomly divided into two groups: control group (n = 27), conventional drug treatment (including hypoglycemic, antihypertensive, lipid-lowering, antiplatelet etc.); probucol group Based on oral probucol tablets 0.5g, 2 times a day orally, two groups of treatment for 3 months. The levels of microalbuminuria, blood glucose, blood lipids, high-sensitivity C-reactive protein and fibrinogen in the two groups before and after treatment were compared. Results Compared with before treatment, blood glucose, blood lipid, blood pressure and urine microalbumin were significantly decreased in both groups after treatment (P <0.05). There was no significant difference in blood glucose, blood lipid and blood pressure between the two groups after treatment > 0.05). However, hs-CRP, fibrinogen and urine microalbumin in probucol group were significantly lower than those in the conventional drug group, with significant difference between the two groups (P <0.05). Conclusion On the basis of routine drug therapy, combined with probucol, can effectively reduce the urine microalbumin, the treatment of early diabetic nephropathy.